P1A-derived peptide–MHC class I complex (P1A-MHC I complex)

The P1A-derived peptide–MHC class I complex is a well-characterized tumor-specific antigen complex primarily utilized in murine cancer models, such as the P815 mastocytoma (Source: NIH, PubMed). It consists of a specific peptide fragment (often the LPYLGWLVF decapeptide) derived from the P1A protein, which is presented on the cell surface by the MHC class I molecule H-2Ld (Source: NIH, ResearchGate). P1A is a cancer-germline antigen, meaning it is expressed in various tumor types but remains silent in normal tissues, with the exception of immune-privileged sites like the testis and placenta (Source: NIH). This complex serves as a critical target for cytotoxic T lymphocytes (CTLs), which recognize the peptide-MHC assembly via their T-cell receptors (TCRs) to initiate tumor cell destruction (Source: NIH). In the field of immunotherapy, the P1A-MHC I complex is a foundational model for studying T-cell responses, tolerance, and the development of TCR-based therapies, paralleling human MAGE-type antigens (Source: NIH). Therapeutic strategies targeting this complex include peptide-based vaccines and adoptive T-cell transfers designed to enhance the immune system's ability to identify and eliminate P1A-expressing malignant cells (Source: NIH). Research on this target has provided significant insights into the mechanisms of cross-presentation and the role of costimulation in tumor rejection (Source: ResearchGate). Despite its high immunogenicity, tumors can evade recognition through the downregulation of MHC class I molecules or the selection of antigen-loss variants (Source: NIH).

Other names

P1A antigenP1A peptide-MHC complexH-2Ld-P1A complexTumor-associated antigen P1AP815A antigenTrap1a-derived antigen

Recognition of the peptide-MHC complex by specific T-cell receptors (TCRs) on CD8+ T cells, leading to the activation of cytotoxic pathways and lysis of the tumor cell.